Bull markets mature into frenzied displays of greed, hope, and naked euphoria before they die. But that last stage can go on sometimes for years, as we saw in the latter half of the 1990’s.
As we climb back toward some version of a normalized operating context for the business economy in 2021 through the roll-out of various vaccine distribution programs, investor enthusiasm, already buoyed by record monetary and fiscal stimulus support, is verging on bubble levels.
That has driven speculative plays into gear with newfound momentum, which could drive the market’s attitude during the first quarter of this year, opening up opportunities for dramatic speculative gains for savvy market participants.
With that in mind, we take a look at some interesting small-cap momentum movers with interesting stories and momentum, including: BioNano Genomics Inc (NASDAQ:BNGO), Mind Medicine (MindMed) Inc (OTCMKTS:MMEDF), Limitless Venture Group Inc (OTCMKTS:LVGI), and HIVE Blockchain Technologies Ltd (OTCMKTS:HVBTF).
BioNano Genomics Inc (NASDAQ:BNGO) promulgates itself as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company’s Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing.
BioNano Genomics Inc (NASDAQ:BNGO) most recently announced the publication in the Journal of Personalized Medicine by Lineagen, its CLIA certified diagnostic services subsidiary, of an analysis of Professor Temple Grandin’s genome in one of the most comprehensive evaluations of a single genome of a high functioning individual with Autism Spectrum Disorder (ASD).
According to the release, through use of the Lineagen’s suite of genetic tests customized for individuals with ASD and other disorders of childhood development, including FirstStepDx PLUS chromosomal microarray, NextStepDx PLUS whole exome sequencing, and whole genome sequencing, the study identified novel variants in known ASD risk genes and other genetic variants important to her health and wellness. Despite Dr. Grandin’s high level of functioning and acute awareness of how her ASD manifests, these findings have led to improved clinical management of many of her symptoms.
And the stock has been acting well over recent days, up something like 460% in that time. Shares of the stock have powered higher over the past month, rallying roughly 886% in that time on strong overall action.
BioNano Genomics Inc (NASDAQ:BNGO) generated sales of $2.2M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 85.8% on the top line. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($18.9M against $24.8M, respectively).
Mind Medicine (MindMed) Inc (OTCMKTS:MMEDF) promulgates itself as a leading psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness.
The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the Company’s groundbreaking approach to developing the next generation of psychedelic inspired medicines and therapies.
Mind Medicine (MindMed) Inc (OTCMKTS:MMEDF) most recently announced that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp.
According to the release, the Lead Underwriter has agreed, on behalf of a syndicate of underwriters, to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 18,200,000 units of the Company at a price of C$4.40 per Unit for aggregate gross proceeds to the Company of C$80,080,000.
The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 48% in that timeframe. Shares of the stock have powered higher over the past month, rallying roughly 227% in that time on strong overall action.
Mind Medicine (MindMed) Inc (OTCMKTS:MMEDF) had no reported sales in its last quarterly financial data. However, the company has a strong balance sheet, with cash levels far outweighing current liabilities ($18M against $4M, respectively).
Limitless Venture Group Inc (OTCMKTS:LVGI) promulgates itself as a company that provides its shareholders with access to leading small and medium-sized businesses focused on growth.
Leveraging its permanent capital base, disciplined long-term approach, and actionable expertise, LVGI owns controlling interests in its subsidiaries as it partners with management teams to build businesses with the capacity to unlock significant value for its shareholders.
One way to think about this model is as a small-cap Berkshire Hathaway or a publicly traded private equity firm. It drives growth through both strategic and organic pathways by acquiring promising subsidiaries and augmenting their access to key resources and talent.
Limitless Venture Group Inc (OTCMKTS:LVGI) most recently announced that it has contracted EDM Media LLC, a leading Public Relations and Media firm, to broaden the Company’s presence and visibility on social and digital media and help communicate LVGI’s message and vision to a wider audience as the Company expands its operations and achievements in 2021.
“We believe in our vision at LVGI and feel it is in our shareholders’ best interest to tell our story to the world as we build toward powerful performance and tangible results in the new year,” stated Joseph Francella, CEO of Limitless Venture Group. “I am excited that the talented team at EDM is set to help drive that expanded visibility. They have a tremendous track record of success, and we fully expect our message to reach a much wider audience and be well received in the process.”
The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 8% in that timeframe.
Limitless Venture Group Inc (OTCMKTS:LVGI) has put in place the potential for strong topline growth as it begins to reap the benefits of its recent acquisitions, which are positioned to drive cash flows from operations in 2021, according to company materials.
HIVE Blockchain Technologies Ltd (OTCMKTS:HVBTF) is a leading player in the crypto mining investment thematic landscape. HIVE owns state-of-the-art green energy-powered data centre facilities in Canada, Sweden, and Iceland which produce newly minted digital currencies like Bitcoin and Ethereum continuously on the cloud.
The company’s deployments provide shareholders with exposure to the operating margins of digital currency mining as well as a portfolio of crypto coins.
HIVE Blockchain Technologies Ltd (OTCMKTS:HVBTF) recently announced that it has entered into a non-binding, exclusive memorandum of understanding (MOU) with GPU.One Holding Inc to expand HIVE’s Canadian footprint through the potential purchase of GPU Atlantic Inc.
“We are excited about this opportunity for HIVE to expand our Canadian footprint through the acquisition of this data centre campus which has access to 50 megawatts (MW) of low-cost green power in Grand Falls, New Brunswick,” said Frank Holmes, Interim Executive Chairman of HIVE. “Further, and important to building our vision, is the GPU.One team of young, skilled and proven data centre professionals with deep high density data centre build out and maintenance experience who will take on executive positions within HIVEs organization.”
The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 57% in that timeframe. Shares of the stock have powered higher over the past month, rallying roughly 200% in that time on strong overall action.
HIVE Blockchain Technologies Ltd (OTCMKTS:HVBTF) pulled in sales of $17.3M in its last reported quarterly financials, representing top line growth of 9.2%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($22.1M against $12.6M).